Clinical Trial: A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07471048) titled 'A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis' on March 10.

Brief Summary: The goal of this clinical trial is to evaluate whether Viv, a consumer-grade dietary supplement derived from the Magnolia officinalis plant, has an effect on biomarkers of immune activity in adults with psoriasis. To address this question, this trial will compare Viv to a placebo (a look-alike substance that contains no drug).

Participants will:

* Take Viv or a placebo every day for 3 months.

* Complete electronic questionnaires about their quality of life and psoriasis symptoms...